Viral Vector Process Development & Manufacturing FAQs
Viral vector manufacturing is at a critical inflection point as gene therapies advance toward late-stage clinical development and commercialisation. This FAQ page addresses the most pressing scientific, technical, regulatory, and operational questions facing viral vector process development and manufacturing leaders today.
Whether you are optimising upstream yields, scaling downstream purification, preparing for regulatory scrutiny, or selecting CDMO partners, these answers reflect the real-world challenges discussed by experts at the Viral Vector Process Development & Manufacturing Summit.
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.